Tirzepatide (GLP-2) 30 mg

▎ Ọdịdị Tirzepatide

▎ Nyocha Tirzepatide

Kedu ihe ndabere nyocha nke Tirzepatide?

Nchọpụta nyocha nke Tirzepatide bụ isi sitere na nyocha nke ọgwụ ọgwụgwọ metabolism na ọchịchọ maka ọgwụ nchịkwa ibu. Ọgwụ ọgwụgwọ metabolism ọdịnala nwere oke, ebe GLP-1 agonists ndị na-anabata ya na-egosipụta nrụpụta dị ukwuu n'ịkwalite njikwa glucose ọbara, na-akpali ndị nyocha imepụta ọgwụ dị irè nke otu klas ahụ. Dị ka onye na-anabata GIP/GLP-1 dual agonist, Tirzepatide nwere ike ịhazi ọkwa glucose ọbara nke ọma. Mmụba zuru ụwa ọnụ nke oke ibu na oke ibu emewo ka njikwa ibu bụrụ mkpa ụlọ ọgwụ ngwa ngwa. Ndị na-anabata GLP-1 nwere mmetụta na-ebelata ibu, na-eme ka ha bụrụ ebumnuche maka mbelata ibu. Tirzepatide enwetala nlebara anya n'ihi nsonaazụ mbelata ibu dị mma ya.

Kedu ihe bụ usoro nke Tirzepatide?

Ọrụ agonist receptor abụọ: 

Tirzepatide bụ glucagon-dị ka peptide-1 (GLP-1) na glucose na-anabata insulinotropic polypeptide (GIP) agonist [1,2] (Wong E, 2023; Kumar D, 2022). GLP-1 na GIP bụ homonụ incretin na-emepụta n'ime eriri afọ, na-arụ ọrụ dị mkpa n'ịkwado glucose homeostasis. Tirzepatide na-arụ ọrụ synergistic site n'ịgbalite GLP-1 na ndị na-anabata GIP n'otu oge, si otú a na-achịkwa ọkwa glucose ọbara.

Usoro insulin na mmepụta glucagon: + 

Ọ na-abawanye njikọ insulin na nzuzo ma na-ebelata ntọhapụ glucagon n'ụzọ dabere na glucose. Mgbe ọkwa glucose dị n'ọbara na-ebili, Tirzepatide na-akpali sel β-pancreatic na-ezochi insulin, na-akwalite nnabata glucose na itinye n'ọrụ, si otú a na-ebelata ọkwa glucose ọbara; N'otu oge, ọ na-egbochi mkpụrụ ndụ α-pancreatic site na nzuzo glucagon, na-ebelata mmepụta glucose imeju, na-ebelata ọkwa glucose ọbara, na-achịkwa nke ọma ibu ọnụ na ọkwa glucose ọbara postprandial ^[1,3]..

Usoro ọrụ ndị ọzọ: 

Tirzepatide na-akwalitekwa satiety, nke nwere ike jikọta ya na ịgbalite GLP-1 ndị na-anabata ya, na-eme ihe na usoro nhụjuanya nke etiti, na-emetụta ụlọ ọrụ na-achịkwa agụụ, na-eduga ndị ọrịa iji belata ihe oriri ma si otú a na-enyere aka na ọnwụ. Ọ na-egbu oge ịpụpụ afọ, na-agbatị oge nri na-adị n'ime afọ ma jiri nwayọọ nwayọọ na-abanye n'ime eriri afọ, si otú a na-egbochi mmụba ngwa ngwa na ọkwa glucose ọbara ^[1]..

Ọgụgụ 1 Usoro ọrụ nke T irzepatide ^[6].

Kedu ihe bụ ngwa T irzepatide?

Ọgwụgwọ nke ụdị 2 metabolism: 

A kwadoro Tirzepatide maka ọgwụgwọ ndị okenye nwere ụdị 2 metabolism dị ka ihe mgbakwunye nri na mmega ahụ. Nnwale SURPASS gosipụtara na Tirzepatide na-ebelata nke ukwuu hemoglobin A1c (HbA1c), na mbelata sitere na -1.87% ruo -2.59% (-20 ruo -28 mmol/mol). Ọ na-egosipụtakwa njikwa glycemic dị elu ma e jiri ya tụnyere ụfọdụ agonists GLP-1 nnabata, dị ka semaglutide 1 mg na nnwale SUPRASS-2. Na mgbakwunye, ọ nwere ike belata ibu ahụ, yana oke ibu sitere na -6.2 ruo -12.9 n'arọ na ọmụmụ ụlọ ọgwụ, nke dị oke mkpa maka ndị ọrịa nwere ụdị metabolism 2 nke na-enwekarị oke ibu ma ọ bụ oke ibu ^[1,4]..

Ọgwụgwọ oke ibu: 

Ebe ọ bụ na Tirzepatide na-akwalite satiety, na-ebelata iri nri, ma na-akwalite ibu ibu, ọ nwere uru ọgwụgwọ maka ndị ọrịa nwere oke ibu. Nnyocha na-egosi na ọ nwere ike belata ibu site na 20%, melite ọnọdụ ndị ọrịa 'metabolism, ma na-eje ozi dị ka nhọrọ ọgwụgwọ ọhụrụ maka oke ibu, na-enyere ndị ọrịa buru ibu aka ịkwụsị ibu ma belata ihe ize ndụ nke ọrịa dị iche iche metụtara oke ibu ^[1,2]..

Mbelata ihe ize ndụ nke ọrịa obi: 

Ndị ọrịa nwere ụdị metabolism nke 2 na-echekarị ihe ize ndụ dị ukwuu nke ọrịa obi. Na mgbakwunye na iwetulata shuga na ibu ọbara, Tirzepatide nwere mmetụta dị mma na ihe ngosi metụtara obi, gụnyere ibelata ọbara mgbali elu, ibelata mkpokọta abụba visceral, na ibelata ọkwa triglyceride na-ekesa, si otú a na-enyere aka belata ihe ize ndụ nke ọrịa obi ma melite nsonaazụ obi ndị ọrịa ^[4]..

Ọgwụgwọ enwere ike maka steatohepatitis na-abụghị mmanya (NASH): 

Tirzepatide nwere mmetụta ọgwụgwọ nwere ike na NASH. Site na imeziwanye uche insulin na ịhazi glucose na metabolism lipid, ọ nwere ike belata steatosis imeju na mbufụt, na-enye ntụziaka ọhụrụ maka ọgwụgwọ NASH ^[5].

Mmechi

Dị ka GIP/GLP-1 dual agonist receptor, Tirzepatide egosila mmetụta dị ịrịba ama na ọgwụgwọ nke metabolism na nsogbu metabolic. Site n'ịhazi insulin na glucagon secretion, na-egbu oge ịwụsa afọ, na ime ka satiety dịkwuo elu, ọ na-ebelata ọkwa hemoglobin A1c nke ọma ma na-ebelata ibu onye ọrịa. Na mgbakwunye, ọgwụ ahụ na-eme ka ihe egwu dị egwu nke obi dị ka ọkwa lipid na ọbara mgbali elu ma gosipụta ịdị irè na steatohepatitis na-abụghị mmanya.

Banyere Onye dere ya

Ihe niile a kpọtụrụ aha n'elu bụ Cocer Peptides na-enyocha, dezie ma chịkọta ya.

Onye ode akwụkwọ akụkọ sayensị

De Block C jikọtara ya na Mahadum Antwerp na ụlọ ọrụ ndị metụtara ya na Belgium, gụnyere Inflamed Ctr Excellence, University Hospital Antwerp (UZA na Univ Hosp Antwerp), na Infla Med Ctr Excellence. Nnyocha ya gbasara ọtụtụ ọzụzụ, dị ka Endocrinology & Diabetes, ebe ọ na-elekwasị anya na homonụ na nsogbu metabolic; Gastroenterology & Hepatology, ịchọpụta ọrịa digestive na imeju; General & Internal Medicine, na-agwa nchoputa na njikwa nke ọrịa ndị nkịtị; Nutrition & Dietetics, nyocha ihe oriri na mmetụta ahụike ya; na Urology & Nephrology, na-amụ pathology na ụlọ ọgwụ omume nke urinary na akụrụ ọrịa. Ọ bụ ọkà mmụta nwere nnukwu onyinye n'ọtụtụ ngalaba ahụike. De Block C ka edepụtara na ntụaka nke ntụaka [4].

▎ Okwu ndị dị mkpa

[1] Wong E, Cope R, Dima L, et al. Tirzepatide: A Dual Glucose-based Insulinotropic Polypeptide na Glucagon-dị ka Peptide-1 Agonist maka njikwa nke ụdị 2 ọrịa shuga mellitus[J]. Akwụkwọ akụkọ American Therapeutics, 2023,30 (1): e26-e35.DOI: 10.1097/MJT.0000000000001588.

[2] Kumar D, Harshidha D, Mousigan M, et al. Nkọwa na Tirzepatide, Ọgwụgwọ Abụọ Ezubere maka Ọrịa shuga na oke ibu[J]. Akwụkwọ akụkọ mba ụwa nke nyocha ọhụụ na uto, 2022,7:983.DOI:10.5281/zenodo.7420605.

[3] Sweta, Gupta S, Bansal S, et al. Tirzepatide akwụkwọ akụkọ na-egbochi ọrịa shuga na-ekpughere ihe omume abụọ [J]. Chọpụta ahụike ọha, 2024,21 (1): 75.DOI: 10.1186 / s12982-024-00200-2.

[4] De Block C, Bailey C, Wysham C, et al. Tirzepatide maka ọgwụgwọ ndị okenye nwere ụdị 2 metabolism: Echiche endocrine [J]. Ọrịa shuga oke ibu & Ọrịa shuga, 2023,25 (1): 3-17.DOI: 10.1111/dom.14831.

[5] Sood A, Kaur P, Syed O, et al. Na-agbanwegharị nlekọta metabolism: ikpughe ikike Tirzepatide na njikwa glycemic na karịa [J]. Nyocha ọkachamara nke Clinical Pharmacology, 2024,17 (3): 235-246.DOI: 10.1080/17512433.2024.2310070.

[6] Grover-Páez F, Gómez A, Suárez A, et al. Site na usoro glycocentric n'ime onye ọrịa nwere ụdị 2 metabolism na-eme ka ọ bụrụ ọgwụgwọ mgbochi ọtụtụ akụkụ yana mbelata nsonaazụ neuro-nephro-cardiovascular.[M]//2023.DOI: 10.5772/intechopen.1002363.

Edemede na ozi ngwaahịa niile enyere na webụsaịtị a bụ naanị maka mgbasa ozi na ebumnuche mmụta.  

Ngwaahịa ndị enyere na webụsaịtị a bụ naanị maka nyocha in vitro. A na-eme nyocha in vitro (Latin: * na iko *, nke pụtara na ihe eji enyo) na mpụga ahụ mmadụ. Ngwaahịa ndị a abụghị ọgwụ, ndị US Food and Drug Administration (FDA) akwadobeghị ya, ha agaghịkwa eji ya gbochie, gwọọ, ma ọ bụ gwọọ ọnọdụ ahụike ọ bụla, ọrịa, ma ọ bụ ọrịa. Iwu amachibidoro nke ọma iwebata ngwaahịa ndị a n'ime ahụ mmadụ ma ọ bụ anụmanụ n'ụdị ọ bụla.